PF-Atlas › Clinical Trials › NCT03981094

A Study of the Pharmacokinetic Interaction Between Pirfenidone and BMS-986278 in Healthy Participants

BMS-986278 · Phase 1

Registry ID
NCT03981094
Phase
Phase 1
Status
Completed
Drug / intervention
BMS-986278
Sponsor
Bristol-Myers Squibb
Start
2019-05-10
Enrollment
22
Locations
1

About this trial

The main objectives of this study are to characterize the PK of BMS-986278 after administration of a single dose of BMS-986278 alone or in combination with pirfenidone, as well as to characterize the PK of pirfenidone after administration of a single dose of pirfenidone alone or in combination with BMS-986278

View NCT03981094 on ClinicalTrials.gov →

Explore related

Admilparant / BMS-986278 — Treatment profileAll BMS-986278 trialsAll IPF trials

Related trials

BMS-986278 — NCT05932303BMS-986278 — NCT06003426BMS-986278 — NCT05985590BMS-986278 — NCT06025578
Medical disclaimer. This page summarizes public trial data for NCT03981094 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.